Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry

Journal of Interventional Cardiology - Tập 2019 - Trang 1-10 - 2019
Francesco Burzotta1,2, Giulio Russo1,2, Flavio Ribichini3, Anna Piccoli3, Domenico D’Amario1,2, Lazzaro Paraggio1,2, Leonardo Previ1,2, Gabriele Pesarini3, Italo Porto1,2, Antonio Maria Leone1,2, Giampaolo Niccoli1,2, Cristina Aurigemma1,2, Diana Verdirosi1,2, Filippo Crea1,2, Carlo Trani1,2
1Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
2Università Cattolica Del Sacro Cuore, Roma, Italy
3Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy

Tóm tắt

Objective. To investigate the effect of extent of revascularization in complex high-risk indicated patients (CHIP) undergoing Impella-protected percutaneous coronary intervention (PCI). Background. Complete revascularization has been shown to be associated with improved outcomes. However, the impact of more complete revascularization during Impella-protected PCI in CHIP has not been reported. Methods. A total of 86 CHIP undergoing elective PCI with Impella 2.5 or Impella CP between April 2007 and December 2016 from 2 high volume Italian centers were included. Baseline, procedural, and clinical outcomes data were collected retrospectively. Completeness of coronary revascularization was assessed using the British Cardiovascular Intervention Society myocardial jeopardy score (BCIS-JS) derived revascularization index (RI). The primary end-point was all-cause mortality. A multivariate regression model was used to identify independent predictors of mortality. Results. All patients had multivessel disease and were considered unsuitable for surgery. At baseline, 44% had left main disease, 78% had LVEF ≤ 35%, and mean BCIS-JS score was 10±2. The mean BCIS-JS derived RI was 0.7±0.2 and procedural complications were uncommon. At 14-month follow-up, all-cause mortality was 10.5%. At follow-up, 67.4% of CHIP had LVEF ≥ 35% compared to 22.1% before Impella protected-PCI. Higher BCIS-JS RI was significantly associated with LVEF improvement (p=0.002). BCIS-JS RI of ≤ 0.8 (HR 0.11, 95% CI 0.01- 0.92, and p = 0.042) was an independent predictor of mortality. Conclusions. These results support the practice of percutaneous Impella use for protected PCI in CHIP. A more complete revascularization was associated with significant LVEF improvement and survival.

Từ khóa


Tài liệu tham khảo

10.1016/j.ijcard.2015.07.065

10.1161/CIRCULATIONAHA.116.022061

10.1016/j.jcin.2008.11.005

10.1161/CIRCULATIONAHA.112.098194

10.1016/j.jacc.2009.09.018

10.1002/ccd.23403

10.1177/2048872617717687

10.1007/s00392-018-1230-6

10.1016/j.jcin.2018.02.028

2018, Minerva Cardioangiologica, 66, 612

10.1016/j.ahj.2009.09.015

10.1016/j.amjcard.2012.09.012

10.4330/wjc.v6.i8.836

10.2459/JCM.0b013e3282f9abe7

2019, Journal of Invasive Cardiology, 31, E37

2018, Minerva Cardioangiologica, 66, 606

10.1093/eurheartj/ehq406

10.1161/circulationaha.110.009449

10.1038/nrcardio.2012.122

2015, Journal of the American Society of Echocardiography, 28, 1, 10.1016/j.echo.2014.10.003

10.1016/j.ijcard.2018.07.064

10.1161/CIRCULATIONAHA.114.011541

10.1016/j.jacc.2012.03.010

2018, Minerva Cardioangiologica, 66, 594

10.1016/j.amjcard.2013.09.008

10.1111/joic.12166

10.1002/ccd.26979

10.1161/CIR.0b013e31823a5596

2010, European Heart Journal, 31, 2501, 10.1093/eurheartj/ehq277